Foundation Funds Research into Biomarkers for Parkinson’ Disease

Mitchell Blunt is a noted physician and businessman who holds both an MD and an MBA. He currently serves as founder and CEO of Consonance Capital, a health care investment firm, and as a clinical assistant professor at Weill Cornell Medical College. In addition, Mitchell Blutt has leveraged his business and medical expertise by previously serving on the board of the Michael J. Fox Foundation for Parkinson’s Research.

The Michael J. Fox Foundation provides funding to seek a cure for Parkinson’s along with improved therapies for those living with the condition. The organization seeks to fund the most promising concepts in Parkinson’s disease research. Biomarkers is one concept currently receiving priority from the foundation. Increased understanding of biomarkers can aid physicians in diagnosing and tracking Parkinson’s disease. In addition, biomarkers can measure the effect of drugs on the disease and help accelerate development of relevant therapies.

Although researchers have not yet identified a clear biomarker for Parkinson’s disease, the foundation is devoting resources to support biomarker discovery. Currently, the foundation is sponsoring two multi-year clinical studies to advance this important goal.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s